Screening Compounds with a Novel High-Throughput ABCB1-Mediated Efflux Assay Identifies Drugs with Known Therapeutic Targets at Risk for Multidrug Resistance Interference

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Ansbro, Megan R ^a   Shukla, Suneet ^a   Ambudkar, Suresh V ^a   Yuspa, Stuart H ^a   Li, Luowei ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 4 (8 CYCLOPENTYL 7 ETHYL 5,6,7,8 TETRAHYDRO 5 METHYL 6 OXO 2 PTERIDINYLAMINO) 3 METHOXY N (1 METHYL 4 PIPERIDINYL)BENZAMIDE; BL 2536; CALCEIN; CYCLOSPORIN A; IKK 16; IODOARYLAZIDOPRAZOSIN I 125; ISPINESIB; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN INHIBITOR; RADIOPHARMACEUTICAL AGENT; TARIQUIDAR; UNCLASSIFIED DRUG; VERAPAMIL;

ARTICLE; BIOACCUMULATION; CANCER CELL CULTURE; DRUG CYTOTOXICITY; DRUG IDENTIFICATION; DRUG SCREENING; FLOW CYTOMETRY; FLUORESCENCE IMAGING; HIGH THROUGHPUT SCREENING; IC 50; ISOTOPE LABELING; MOLECULAR IMAGING; PHOTOAFFINITY LABELING; PROTEIN EXPRESSION; PROTEIN TRANSPORT;

CELL LINE; CYCLOSPORINE; DRUG RESISTANCE, MULTIPLE; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; P-GLYCOPROTEIN; QUINOLINES; REPRODUCIBILITY OF RESULTS; VERAPAMIL;

EID: 84876055711     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060334     Document Type: Article

References (50)

1. Gillet JP, Gottesman MM, (2011) Advances in the molecular detection of ABC transporters involved in multidrug resistance in cancer. Curr Pharm Biotechnol 12: 686-692.
2. Aszalos A, (2007) Drug-drug interactions affected by the transporter protein, P-glycoprotein (ABCB1, MDR1) II. Clinical aspects. Drug Discov Today 12: 838-843.
3. Borst P, Elferink RO, (2002) Mammalian ABC transporters in health and disease. Annu Rev Biochem 71: 537-592.
4. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM, (2006) Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5: 219-234.
5. Tachibana T, Kato M, Takano J, Sugiyama Y, (2010) Predicting drug-drug interactions involving the inhibition of intestinal CYP3A4 and P-glycoprotein. Curr Drug Metab 11: 762-777.
6. Shen DW, Pastan I, Gottesman MM, (1988) In situ hybridization analysis of acquisition and loss of the human multidrug-resistance gene. Cancer Res 48: 4334-4339.
7. Slovak ML, Hoeltge GA, Dalton WS, Trent JM, (1988) Pharmacological and biological evidence for differing mechanisms of doxorubicin resistance in two human tumor cell lines. Cancer Res 48: 2793-2797.
8. Shukla S, Schwartz C, Kapoor K, Kouanda A, Ambudkar SV, (2012) Use of baculovirus BacMam vectors for expression of ABC drug transporters in mammalian cells. Drug Metab Dispos 40: 304-312.
9. Dalton WS, Cress AE, Alberts DS, Trent JM, (1988) Cytogenetic and phenotypic analysis of a human colon carcinoma cell line resistant to mitoxantrone. Cancer Res 48: 1882-1888.
10. Weaver JL, Pine PS, Aszalos A, Schoenlein PV, Currier SJ, et al. (1991) Laser scanning and confocal microscopy of daunorubicin, doxorubicin, and rhodamine 123 in multidrug-resistant cells. Exp Cell Res 196: 323-329.
11. Kessel D, Beck WT, Kukuruga D, Schulz V, (1991) Characterization of multidrug resistance by fluorescent dyes. Cancer Res 51: 4665-4670.
12. Calcagno AM, Kim IW, Wu CP, Shukla S, Ambudkar SV, (2007) ABC drug transporters as molecular targets for the prevention of multidrug resistance and drug-drug interactions. Curr Drug Deliv 4: 324-333.
13. Sarkadi B, Price EM, Boucher RC, Germann UA, Scarborough GA, (1992) Expression of the human multidrug resistance cDNA in insect cells generates a high activity drug-stimulated membrane ATPase. J Biol Chem 267: 4854-4858.
14. Scarborough GA, (1995) Drug-stimulated ATPase activity of the human P-glycoprotein. J Bioenerg Biomembr 27: 37-41.
15. Ambudkar SV, Lelong IH, Zhang J, Cardarelli CO, Gottesman MM, et al. (1992) Partial purification and reconstitution of the human multidrug-resistance pump: characterization of the drug-stimulatable ATP hydrolysis. Proc Natl Acad Sci U S A 89: 8472-8476.
16. Gottesman MM, (2002) Mechanisms of cancer drug resistance. Annu Rev Med 53: 615-627.
17. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, et al. (1999) Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39: 361-398.
18. Homolya L, Hollo M, Muller M, Mechetner EB, Sarkadi B, (1996) A new method for a quantitative assessment of P-glycoprotein-related multidrug resistance in tumour cells. Br J Cancer 73: 849-855.
19. Tiberghien F, Loor F, (1996) Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay. Anticancer Drugs 7: 568-578.
20. Wang EJ, Casciano CN, Clement RP, Johnson WW, (2001) Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun 289: 580-585.
21. Ivnitski-Steele I, Larson RS, Lovato DM, Khawaja HM, Winter SS, et al. (2008) High-throughput flow cytometry to detect selective inhibitors of ABCB1, ABCC1, and ABCG2 transporters. Assay Drug Dev Technol 6: 263-276.
22. Henrich CJ, Bokesch HR, Dean M, Bates SE, Robey RW, et al. (2006) A high-throughput cell-based assay for inhibitors of ABCG2 activity. J Biomol Screen 11: 176-183.
23. Forster F, Volz A, Fricker G, (2008) Compound profiling for ABCC2 (MRP2) using a fluorescent microplate assay system. Eur J Pharm Biopharm 69: 396-403.
24. Bauer B, Miller DS, Fricker G, (2003) Compound profiling for P-glycoprotein at the blood-brain barrier using a microplate screening system. Pharm Res 20: 1170-1176.
25. Bushway PJ, Mercola M, Price JH, (2008) A comparative analysis of standard microtiter plate reading versus imaging in cellular assays. Assay Drug Dev Technol 6: 557-567.
26. Akiyama S, Fojo A, Hanover JA, Pastan I, Gottesman MM, (1985) Isolation and genetic characterization of human KB cell lines resistant to multiple drugs. Somat Cell Mol Genet 11: 117-126.
27. Shen DW, Cardarelli C, Hwang J, Cornwell M, Richert N, et al. (1986) Multiple drug-resistant human KB carcinoma cells independently selected for high-level resistance to colchicine, adriamycin, or vinblastine show changes in expression of specific proteins. J Biol Chem 261: 7762-7770.
28. Kannan P, Brimacombe KR, Zoghbi SS, Liow JS, Morse C, et al. (2010) N-desmethyl-loperamide is selective for P-glycoprotein among three ATP-binding cassette transporters at the blood-brain barrier. Drug Metab Dispos 38: 917-922.
29. Katayama K, Yoshioka S, Tsukahara S, Mitsuhashi J, Sugimoto Y, (2007) Inhibition of the mitogen-activated protein kinase pathway results in the down-regulation of P-glycoprotein. Mol Cancer Ther 6: 2092-2102.
30. Vizler C, Nagy T, Kusz E, Glavinas H, Duda E, (2002) Flow cytometric cytotoxicity assay for measuring mammalian and avian NK cell activity. Cytometry 47: 158-162.
31. Shen Y, Chu Y, Yang Y, Wang Z, (2012) Mitochondrial localization of P-glycoprotein in the human breast cancer cell line MCF-7/ADM and its functional characterization. Oncol Rep 27: 1535-1540.
32. Li L, Shukla S, Lee A, Garfield SH, Maloney DJ, et al. (2010) The skin cancer chemotherapeutic agent ingenol-3-angelate (PEP005) is a substrate for the epidermal multidrug transporter (ABCB1) and targets tumor vasculature. Cancer Res 70: 4509-4519.
33. Zhang JH, Chung TD, Oldenburg KR, (1999) A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen 4: 67-73.
34. Marques-Santos LF, Oliveira JG, Maia RC, Rumjanek VM, (2003) Mitotracker green is a P-glycoprotein substrate. Biosci Rep 23: 199-212.
35. Roe M, Folkes A, Ashworth P, Brumwell J, Chima L, et al. (1999) Reversal of P-glycoprotein mediated multidrug resistance by novel anthranilamide derivatives. Bioorg Med Chem Lett 9: 595-600.
36. Cornwell MM, Pastan I, Gottesman MM, (1987) Certain calcium channel blockers bind specifically to multidrug-resistant human KB carcinoma membrane vesicles and inhibit drug binding to P-glycoprotein. J Biol Chem 262: 2166-2170.
37. Tamai I, Safa AR, (1991) Azidopine noncompetitively interacts with vinblastine and cyclosporin A binding to P-glycoprotein in multidrug resistant cells. J Biol Chem 266: 16796-16800.
38. Goldberg H, Ling V, Wong PY, Skorecki K, (1988) Reduced cyclosporin accumulation in multidrug-resistant cells. Biochem Biophys Res Commun 152: 552-558.
39. Crowley E, Callaghan R, (2010) Multidrug efflux pumps: drug binding - gates or cavity? FEBS J 277: 530-539.
40. Mandal D, Moitra K, Ghosh D, Xia D, Dey S, (2012) Evidence for modulatory sites at the lipid-protein interface of the human multidrug transporter P-glycoprotein. Biochemistry 51: 2852-2866.
41. Martin C, Berridge G, Higgins CF, Mistry P, Charlton P, et al. (2000) Communication between multiple drug binding sites on P-glycoprotein. Mol Pharmacol 58: 624-632.
42. Maki N, Hafkemeyer P, Dey S, (2003) Allosteric modulation of human P-glycoprotein. Inhibition of transport by preventing substrate translocation and dissociation. J Biol Chem 278: 18132-18139.
43. Ghosh RD, Chakraborty P, Banerjee K, Adhikary A, Sarkar A, et al. (2012) The molecular interaction of a copper chelate with human P-glycoprotein. Mol Cell Biochem 364: 309-320.
44. Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, et al. (2008) Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 7: 1851-1863.
45. Degenhardt Y, Lampkin T, (2010) Targeting Polo-like kinase in cancer therapy. Clin Cancer Res 16: 384-389.
46. Haupenthal J, Bihrer V, Korkusuz H, Kollmar O, Schmithals C, et al. (2012) Reduced Efficacy of the Plk1 Inhibitor BI 2536 on the Progression of Hepatocellular Carcinoma due to Low Intratumoral Drug Levels. Neoplasia 14: 410-419.
47. Glavinas H, von Richter O, Vojnits K, Mehn D, Wilhelm I, et al. (2011) Calcein assay: a high-throughput method to assess P-gp inhibition. Xenobiotica 41: 712-719.
48. Sankaranarayanan S, Kellner-Weibel G, de la Llera-Moya M, Phillips MC, Asztalos BF, et al. (2011) A sensitive assay for ABCA1-mediated cholesterol efflux using BODIPY-cholesterol. J Lipid Res 52: 2332-2340.
49. Henrich CJ, Robey RW, Bokesch HR, Bates SE, Shukla S, et al. (2007) New inhibitors of ABCG2 identified by high-throughput screening. Mol Cancer Ther 6: 3271-3278.
50. Xiao Y, Davidson R, Smith A, Pereira D, Zhao S, et al. (2006) A 96-well efflux assay to identify ABCG2 substrates using a stably transfected MDCK II cell line. Mol Pharm 3: 45-54.